1369405-90-2Relevant articles and documents
Synthesis and biological evaluation of SGLT2 inhibitors: Gem-difluoromethylenated Dapagliflozin analogs
Chen, Zeng-Hao,Wang, Ruo-Wen,Qing, Feng-Ling
, p. 2171 - 2176 (2012/05/07)
Dapagliflozin is currently the most advanced SGLT2 inhibitor, which has been used in Phase III clinical trials for treatment of diabetes. Here we describe the design and synthesis of Dapagliflozin analogs modified with gem-difluoromethylene group. Their b